Search

Your search keyword '"Kerbel, Robert S."' showing total 142 results
Start Over Author "Kerbel, Robert S." Publication Year Range Last 3 years
142 results on '"Kerbel, Robert S."'

2. Potentiating Salvage Radiotherapy in Radiorecurrent Prostate Cancer Through Anti-CTLA4 Therapy: Implications from a Syngeneic Model.

Author

Wang, Hanzhi, Gong, Linsey, Huang, Xiaoyong, White, Stephanie D., Chung, Hans T., Vesprini, Danny, Petchiny, Tera N., Fokas, Emmanouil, He, Hansen, Kerbel, Robert S., and Liu, Stanley K.

Abstract

Simple Summary: Advanced prostate cancer (PCa) is a prominent contributor to cancer-related fatalities and is associated with significant morbidity and mortality. Currently, addressing the local recurrence of the disease after radiation therapy (RT) poses a significant clinical challenge. We established the first syngeneic model of radiorecurrent PCa to evaluate the effectiveness of immune checkpoint inhibitors (ICIs) in combination with high-dose ionizing radiation (IR). We observed an enhanced anti-tumor response, which led to a delay in tumor growth and, in some cases, a complete elimination of tumors when combining IR with anti-CTLA4. This improvement was linked to an enhanced activation of total T cells, CD4+ helper T cells, and CD8+ cytotoxic T cells in both the draining lymph node and tumor. These results hold substantial potential for translation into clinical practice, serving as a proof of concept for the application of brachytherapy and immune checkpoint inhibitors (ICIs) in cases of recurrent disease. High-risk prostate cancer (PCa) is a leading cause in cancer death and can elicit significant morbidity and mortality. Currently, the salvage of local disease recurrence after radiation therapy (RT) is a major clinical problem. Immune checkpoint inhibitors (ICIs), which enhance immune activation, have demonstrated clinical therapeutic promise in combination with ionizing radiation (IR) in certain advanced cancers. We generated the TRAMP-C2 HF radiorecurrent syngeneic mouse model to evaluate the therapeutic efficacy of ICIs in combination with RT. The administration of anti-PDL1 and/or anti-CTLA4 did not achieve a significant tumor growth delay compared to the control. The combination of IR and anti-PDL1 did not yield additional a growth delay compared to IR and the isotype control. Strikingly, a significant tumor growth delay and complete cure in one-third of the mice were seen with the combination of IR and anti-CTLA4. Immune cells in tumor-draining lymph nodes and tumor-infiltrating lymphocytes from mice treated with IR and anti-CTLA4 demonstrated an upregulation of genes in T-cell functions and enrichment in both CD4+ and CD8+ T-cell populations compared to mice given IR and the isotype control. Taken together, these results indicate enhancement of T-cell response in radiorecurrent PCa by IR and anti-CTLA4. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Abstract 3998: Metronomic gemcitabine plus neratinib effectively inhibits the growth of human Her-2 positive breast cancer cells intracranially implanted into immunodeficient mice

Author

Batson, Serina, primary, Sanchez, Alejandro, additional, Padilla, Hector M., additional, Prospero, Diana L., additional, Lugo, Brenda, additional, Lopez, Valeria V., additional, Estrada, Daniella E., additional, De Avila, Nydia, additional, Darvishi, Saeedeh, additional, Levario, Arlene, additional, Man, Shan, additional, Xu, Ping, additional, Kerbel, Robert S., additional, Bocci, Guido, additional, and Francia, Giulio, additional

Published
2023
Full Text
View/download PDF

6. Supplementary Figure Legends 1-2 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Author

Francia, Giulio, primary, Shaked, Yuval, primary, Hashimoto, Kae, primary, Sun, John, primary, Yin, Melissa, primary, Cesta, Carolyn, primary, Xu, Ping, primary, Man, Shan, primary, Hackl, Christina, primary, Stewart, Julie, primary, Uhlik, Mark, primary, Dantzig, Anne H., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

7. Data from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Author

Francia, Giulio, primary, Shaked, Yuval, primary, Hashimoto, Kae, primary, Sun, John, primary, Yin, Melissa, primary, Cesta, Carolyn, primary, Xu, Ping, primary, Man, Shan, primary, Hackl, Christina, primary, Stewart, Julie, primary, Uhlik, Mark, primary, Dantzig, Anne H., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 1 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Author

Francia, Giulio, primary, Shaked, Yuval, primary, Hashimoto, Kae, primary, Sun, John, primary, Yin, Melissa, primary, Cesta, Carolyn, primary, Xu, Ping, primary, Man, Shan, primary, Hackl, Christina, primary, Stewart, Julie, primary, Uhlik, Mark, primary, Dantzig, Anne H., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Video 3 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Author

Francia, Giulio, primary, Shaked, Yuval, primary, Hashimoto, Kae, primary, Sun, John, primary, Yin, Melissa, primary, Cesta, Carolyn, primary, Xu, Ping, primary, Man, Shan, primary, Hackl, Christina, primary, Stewart, Julie, primary, Uhlik, Mark, primary, Dantzig, Anne H., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

13. Supplementary materials and methods and legends for Supplementary Figures and Tables from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors

Author

Kuczynski, Elizabeth A., primary, Krueger, Janna, primary, Chow, Annabelle, primary, Xu, Ping, primary, Man, Shan, primary, Sundaravadanam, Yogi, primary, Miller, Jessica K., primary, Krzyzanowski, Paul M., primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Video 4 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Author

Francia, Giulio, primary, Shaked, Yuval, primary, Hashimoto, Kae, primary, Sun, John, primary, Yin, Melissa, primary, Cesta, Carolyn, primary, Xu, Ping, primary, Man, Shan, primary, Hackl, Christina, primary, Stewart, Julie, primary, Uhlik, Mark, primary, Dantzig, Anne H., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Video 2 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Author

Francia, Giulio, primary, Shaked, Yuval, primary, Hashimoto, Kae, primary, Sun, John, primary, Yin, Melissa, primary, Cesta, Carolyn, primary, Xu, Ping, primary, Man, Shan, primary, Hackl, Christina, primary, Stewart, Julie, primary, Uhlik, Mark, primary, Dantzig, Anne H., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 2 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Author

Francia, Giulio, primary, Shaked, Yuval, primary, Hashimoto, Kae, primary, Sun, John, primary, Yin, Melissa, primary, Cesta, Carolyn, primary, Xu, Ping, primary, Man, Shan, primary, Hackl, Christina, primary, Stewart, Julie, primary, Uhlik, Mark, primary, Dantzig, Anne H., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Video 1 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Author

Francia, Giulio, primary, Shaked, Yuval, primary, Hashimoto, Kae, primary, Sun, John, primary, Yin, Melissa, primary, Cesta, Carolyn, primary, Xu, Ping, primary, Man, Shan, primary, Hackl, Christina, primary, Stewart, Julie, primary, Uhlik, Mark, primary, Dantzig, Anne H., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

29. Data from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer

Author

Pham, Elizabeth, primary, Yin, Melissa, primary, Peters, Christian G., primary, Lee, Christina R., primary, Brown, Donna, primary, Xu, Ping, primary, Man, Shan, primary, Jayaraman, Lata, primary, Rohde, Ellen, primary, Chow, Annabelle, primary, Lazarus, Douglas, primary, Eliasof, Scott, primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

31. Supplemental Figures 1-5 and Methods from Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer

Author

Pham, Elizabeth, primary, Birrer, Michael J., primary, Eliasof, Scott, primary, Garmey, Edward G., primary, Lazarus, Douglas, primary, Lee, Christina R., primary, Man, Shan, primary, Matulonis, Ursula A., primary, Peters, Christian G., primary, Xu, Ping, primary, Krasner, Carolyn, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

32. Supplemental Figures S1-S6 from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer

Author

Pham, Elizabeth, primary, Yin, Melissa, primary, Peters, Christian G., primary, Lee, Christina R., primary, Brown, Donna, primary, Xu, Ping, primary, Man, Shan, primary, Jayaraman, Lata, primary, Rohde, Ellen, primary, Chow, Annabelle, primary, Lazarus, Douglas, primary, Eliasof, Scott, primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

35. Supplemental Methods from Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer

Author

Pham, Elizabeth, primary, Yin, Melissa, primary, Peters, Christian G., primary, Lee, Christina R., primary, Brown, Donna, primary, Xu, Ping, primary, Man, Shan, primary, Jayaraman, Lata, primary, Rohde, Ellen, primary, Chow, Annabelle, primary, Lazarus, Douglas, primary, Eliasof, Scott, primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Methods and Materials, Figure 1 from Vascular Endothelial Growth Factor–Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth

Author

Ebos, John M.L., primary, Lee, Christina R., primary, Bogdanovic, Elena, primary, Alami, Jennifer, primary, Van Slyke, Paul, primary, Francia, Giulio, primary, Xu, Ping, primary, Mutsaers, Anthony J., primary, Dumont, Daniel J., primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Video 1a from Targeted Anti–Vascular Endothelial Growth Factor Receptor-2 Therapy Leads to Short-term and Long-term Impairment of Vascular Function and Increase in Tumor Hypoxia

Author

Franco, Marcela, primary, Man, Shan, primary, Chen, Limor, primary, Emmenegger, Urban, primary, Shaked, Yuval, primary, Cheung, Alison M., primary, Brown, Allison S., primary, Hicklin, Daniel J., primary, Foster, F. Stuart, primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

45. Data from Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents

Author

Shaked, Yuval, primary, Tang, Terence, primary, Woloszynek, Jill, primary, Daenen, Laura G., primary, Man, Shan, primary, Xu, Ping, primary, Cai, Shi-Rong, primary, Arbeit, Jeffrey M., primary, Voest, Emile E., primary, Chaplin, David J., primary, Smythe, Jon, primary, Harris, Adrian, primary, Nathan, Paul, primary, Judson, Ian, primary, Rustin, Gordon, primary, Bertolini, Francesco, primary, Link, Daniel C., primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

47. Data from Vascular Endothelial Growth Factor–Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth

Author

Ebos, John M.L., primary, Lee, Christina R., primary, Bogdanovic, Elena, primary, Alami, Jennifer, primary, Van Slyke, Paul, primary, Francia, Giulio, primary, Xu, Ping, primary, Mutsaers, Anthony J., primary, Dumont, Daniel J., primary, and Kerbel, Robert S., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results